Advertisement
Wednesday, Dec 08, 2021
Outlook.com
Outlook.com

Revised Covishield Monthly Production Likely To be More Than 120 Million, Covaxin 58 Million: Health Minister

The Department of Biotechnology under the Ministry of Science and Technology has launched 'Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission'.

Revised Covishield Monthly Production Likely To be More Than 120 Million, Covaxin 58 Million: Health Minister
Representational Image | PTI
Revised Covishield Monthly Production Likely To be More Than 120 Million, Covaxin 58 Million: Health Minister
outlookindia.com
2021-08-03T20:13:14+05:30

Citing information from the COVID-19 vaccine manufacturers, the Union Health Minister Mansukh Mandaviya on Tuesday said at the Rajya Sabha that the revised monthly production capacity of Covishield is likely to shot up to more than 120 million doses and of Covaxin to around 58 million doses by December.

This came from Mandaviya while he was responding to a question regarding the current capacity to manufacture Covaxin and Covishield in the country, and the expected capacity going forward from August to December 2021.

"As communicated by the manufacturers, the monthly vaccine production capacity of Covishield is projected to be increased from 110 million doses per month to more than 120 million doses per month and the production capacity of Covaxin is projected to be increased from 25 million doses per month to around 58 million doses per month," the minister said in a written reply.

Further, the Department of Biotechnology under the Ministry of Science and Technology has launched 'Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission'.

The Mission is being implemented by Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking (PSU) of the Department of Biotechnology, the reply stated.

Under the Mission, facility augmentation of Bharat Biotech and one state public sector enterprise and 2 central public sector enterprises (PSEs) -- Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immunologicals Limited (IIL), Hyderabad and Bharat Immunologicals Biologicals Limited (BIBCOL), Bulandshahr -- for production of Covaxin have been supported.

In addition, technology transfer of Covaxin production to Gujarat COVID Vaccine Consortium (GCVC), including Hester Biosciences and OmniBRx Biotechnologies Pvt Ltd, led by Gujarat Biotechnology Research Centre (GBRC) of Department of Science and Technology, Government of Gujarat, has also been facilitated, the reply said.

Further, the Centre has also extended financial assistance to one of the domestic manufacturers for 'At-risk manufacturing', advance payment against the supply orders placed with Serum Institute of India and Bharat Biotech, besides streamlining regulatory norms for approval of vaccines, the reply added. 

(With PTI Inputs)

Advertisement

Outlook Newsletters

Advertisement
Advertisement
Advertisement

Read More from Outlook

Aung San Suu Kyi Verdict 'Disturbing' But Will It Change India's Equation With Myanmar?

Aung San Suu Kyi Verdict 'Disturbing' But Will It Change India's Equation With Myanmar?

While India has time and again appealed for rapprochement between the democratic forces and the military, it has continued to engage with the junta in Myanmar.

Church In India Cosying Up To BJP To Protect Its Interests

Church In India Cosying Up To BJP To Protect Its Interests

What has led to this change of heart over the past few years for the Church, long seen to be anathemic to the Sangh Parivar?

Ashes, 1st Test: Cummins Steals The Show On Rain-Affected Day 1

Ashes, 1st Test: Cummins Steals The Show On Rain-Affected Day 1

Pat Cummins made his captaincy bow in style with a fifer at The Gabba, helping Australia dismiss England for 147. Then rain arrived.

Why AFSPA In Jammu And Kashmir Is Not Just A Defence Act

Why AFSPA In Jammu And Kashmir Is Not Just A Defence Act

Has the AFSPA become an ideological Act, a tool to revise Kashmir history? Many analysts believe so.

Advertisement